Top 100 medical and healthcare startups in USA
May 11, 2026
|
Like
19
1
Funding: $300M
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
2
Funding: $121.5M
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
3
Funding: $106M
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
4
Funding: $65.5M
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system.
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system.
5
Funding: $50M
Serif Biomedicines uses circular DNA with certain chemical modifications to solve several problems that plague traditional gene therapy. Namely, the class of medicines provokes an immune response and is difficult to manufacture. Serif’s approach is to instead use modified DNA that is packaged inside of lipid nanoparticles. This DNA is accompanied by mRNA that, once inside the cell, is turned into proteins that shuttle the DNA into the nucleus, where it can itself be turned into a therapeutic protein.
Serif Biomedicines uses circular DNA with certain chemical modifications to solve several problems that plague traditional gene therapy. Namely, the class of medicines provokes an immune response and is difficult to manufacture. Serif’s approach is to instead use modified DNA that is packaged inside of lipid nanoparticles. This DNA is accompanied by mRNA that, once inside the cell, is turned into proteins that shuttle the DNA into the nucleus, where it can itself be turned into a therapeutic protein.
6
Funding: $20M
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
7
Funding: $15.6M
Insight Health is a clinical AI agent platform that automates patient communication and clinical documentation for medical practices.
Insight Health is a clinical AI agent platform that automates patient communication and clinical documentation for medical practices.
8
Funding: $6.4M
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
9
Funding: $247M
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
10
Funding: $200M
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
11
Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
12
Funding: $407M
Science Corp creates PRIMA retinal implant that has demonstrated in clinical trials the ability to restore vision to patients blinded by the effects of dry advanced macular degeneration. It's a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision. In trials spanning 47 patients across Europe and the U.S., 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words, the company says.
Science Corp creates PRIMA retinal implant that has demonstrated in clinical trials the ability to restore vision to patients blinded by the effects of dry advanced macular degeneration. It's a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision. In trials spanning 47 patients across Europe and the U.S., 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words, the company says.
13
Funding: $358M
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
14
Funding: $203.1M
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
15
Funding: $180M
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
16
Funding: $163M
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
17
Funding: $141M
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
18
Funding: $125M
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
19
Funding: $112.5M
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
20
Funding: $93.9M
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
21
Funding: $89.6M
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
22
Funding: $75M
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
23
Funding: $60M
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
24
Funding: $22M
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
25
Funding: $1.1B
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
26
Funding: $312.1M
Eight Sleep is a sleep fitness company that leverages personal biometrics to restore individuals to their peak energy levels each morning.
Eight Sleep is a sleep fitness company that leverages personal biometrics to restore individuals to their peak energy levels each morning.
27
Funding: $298.3M
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
28
Funding: $287M
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions.
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions.
29
Funding: $200M
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
30
Funding: $160M
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
31
Funding: $109M
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
32
Funding: $95.3M
Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare.
Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare.
33
Funding: $28.6M
Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.
Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.
34
Funding: $25M
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
35
Funding: $16.2M
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
36
Funding: $2M
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
37
Funding: $578.8M
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver and kidney tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver and kidney tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
38
Funding: $496.4M
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
39
Funding: $440.1M
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
40
Funding: $352M
Enable Injections produces wearable delivery devices for injectible drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject up to 20 ml. Such products are called bolus injection systems.
Enable Injections produces wearable delivery devices for injectible drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject up to 20 ml. Such products are called bolus injection systems.
41
Funding: $328M
Grow Therapy helps therapists easily start and grow thriving insurance-accepting practices, giving them the administrative and business tools, peer community support, and pipeline of referrals they need to make their lives better.
Grow Therapy helps therapists easily start and grow thriving insurance-accepting practices, giving them the administrative and business tools, peer community support, and pipeline of referrals they need to make their lives better.
42
Funding: $219.3M
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
43
Funding: $204M
Solace is a digital health platform that connects patients with professional health advocates.
Solace is a digital health platform that connects patients with professional health advocates.
44
Funding: $204M
Solace Health creates healthcare navigation platform that connects patients with experienced expert advocates via phone, text or email. The experts help navigate the care process, whether it's receiving a new diagnosis, finding a doctor, coordinating treatment, obtaining authorizations or managing a chronic condition. The service is covered by Medicare, most Medicare Advantage plans and some insurance companies. The company partners with healthcare providers and offers its own electronic health record card for updates and expert's access to patient medical records to assist with the navigation process.
Solace Health creates healthcare navigation platform that connects patients with experienced expert advocates via phone, text or email. The experts help navigate the care process, whether it's receiving a new diagnosis, finding a doctor, coordinating treatment, obtaining authorizations or managing a chronic condition. The service is covered by Medicare, most Medicare Advantage plans and some insurance companies. The company partners with healthcare providers and offers its own electronic health record card for updates and expert's access to patient medical records to assist with the navigation process.
45
Funding: $182.3M
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
46
Funding: $146.5M
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
47
Funding: $137M
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
48
Funding: $113M
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
49
Funding: $73M
Tava Health is a hybrid platform for mental health services. It partners with employers, individuals and insurance companies, offering online and in-person consultations with psychologists, both in-network and for cash. It enables companies to offer employee benefits, including sponsored therapy at no additional cost or a model that leverages the employee's existing insurance with no additional employer fees. The company's AI algorithm matches each patient with licensed therapists. The company is also provides free practice management platform for behavioral health professionals, integrating an AI-powered clinical secretary, treatment planning, scheduling tools and telemedicine module, and provides payment from over 200 insurance companies within two weeks with chargeback protection.
Tava Health is a hybrid platform for mental health services. It partners with employers, individuals and insurance companies, offering online and in-person consultations with psychologists, both in-network and for cash. It enables companies to offer employee benefits, including sponsored therapy at no additional cost or a model that leverages the employee's existing insurance with no additional employer fees. The company's AI algorithm matches each patient with licensed therapists. The company is also provides free practice management platform for behavioral health professionals, integrating an AI-powered clinical secretary, treatment planning, scheduling tools and telemedicine module, and provides payment from over 200 insurance companies within two weeks with chargeback protection.
50
Funding: $72M
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
